U.S., April 23 -- ClinicalTrials.gov registry received information related to the study (NCT07545356) titled 'A Study of KIVU-305 in Participants With Locally Advanced or Metastatic Solid Tumors' on April 16.
Brief Summary: This is a 2-part, first-in-human, open-label study to determine the safety, tolerability and preliminary efficacy of KIVU-305, a CEACAM5-directed antibody-drug conjugate, in participants with locally advanced or metastatic solid tumors.
Study Start Date: June, 2026
Study Type: INTERVENTIONAL
Condition:
Solid Tumors
Intervention:
DRUG: KIVU-305
KIVU-305 will be administered IV .
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Kivu Bioscience Inc.
Disclaimer: Curated by HT Syndication....